Sanara MedTech Inc. (NASDAQ:SMTI)
| Market Cap | $298.90M+67.1% |
| Revenue (ttm) | $111.91M+9.8% |
| Net Income | -$3.02M+92.0% |
| EPS | -$0.36+91.7% |
| Shares Out | 9.18M |
| PE Ratio | n/a |
| Forward PE | 58.12 |
| Dividend | n/a |
| Ex-Dividend Date | Jul 29, 2027 |
| Volume | 51,189 |
| Open | $32.80 |
| Previous Close | $32.67 |
| Day's Range | $32.44 - $32.86 |
| 52-Week Range | $16.05 - $35.52 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | $35.00(+7.53%) |
| Earnings Date | Mar 23, 2027 |
About SMTI
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Next catalysts
- Mar 23, 2027Earnings report
- Jul 29, 2027Ex-dividend date
$SMTI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SMTI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SMTI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SMTI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SMTI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SMTI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SMTI
| IWMiShares Russell 2000 ETF | $4.02M |
| VTIVanguard Morningstar Total Stock Market ETF | $3.85M |
| IWOiShares Russell 2000 Growth ETF | $1.46M |
| VXFVanguard Extended Market ETF | $1.41M |
| VTWOVanguard Russell 2000 ETF | $942.02K |
| FESMFidelity Enhanced Small Cap ETF | $892.64K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from SMTI’s recent data — informational, not investment advice
What’s Behind the Score
News check: Sanara MedTech surpassed Q3 earnings estimates in concrete business news, showing positive operational performance and beating analyst expectations.
